blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3166617

EP3166617 - A POLOXAMER COMPOSITION FREE OF LONG CIRCULATING MATERIAL AND METHODS FOR PRODUCTION AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.11.2024
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  08.12.2023
FormerGrant of patent is intended
Status updated on  19.07.2023
FormerExamination is in progress
Status updated on  24.11.2017
FormerRequest for examination was made
Status updated on  18.04.2017
FormerThe international publication has been made
Status updated on  07.02.2017
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
LifeRaft Biosciences, Inc.
940 Johnnie Dodds Boulevard
Suite 205
Mt. Pleasant, South Carolina 29464 / US
[2020/29]
Former [2017/20]For all designated states
Mast Therapeutics, Inc.
3611 Valley Centre Drive
Suite 500
San Diego, CA 92130 / US
Inventor(s)01 / EMANUELE, R. Martin
15234 Maple Grove Lane
San Diego, CA 92131 / US
02 / BALASUBRAMANIAN, Mannarsamy
750 Brookfield Parkway
Roswell, GA 30075 / US
03 / SMITH, Stewart.V.
4424 Granger Street
San Diego, CA 92107 / US
 [2017/20]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2024/02]
Former [2017/20]Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB
Landsberger Straße 98
80339 München / DE
Application number, filing date15747613.607.07.2015
[2017/20]
WO2015US39418
Priority number, dateUS201462021697P07.07.2014         Original published format: US 201462021697 P
[2017/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016007537
Date:14.01.2016
Language:EN
[2016/02]
Type: A1 Application with search report 
No.:EP3166617
Date:17.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 14.01.2016 takes the place of the publication of the European patent application.
[2017/20]
Type: B1 Patent specification 
No.:EP3166617
Date:10.01.2024
Language:EN
[2024/02]
Search report(s)International search report - published on:EP14.01.2016
ClassificationIPC:A61K31/77, A61P9/10
[2017/20]
CPC:
A61K31/77 (EP,KR,US); C08G65/30 (KR,US); A61K35/14 (KR,US);
A61K35/18 (KR,US); A61K35/19 (KR,US); A61K9/0019 (KR,US);
A61P1/12 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P7/00 (EP); A61P7/02 (EP);
A61P7/04 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); C08G65/08 (KR,US); A61K2035/124 (KR,US);
C08G2650/58 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/20]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:POLOXAMER ZUSAMMENSETZUNG FREI VON LANG ZIRKULIERENDEM MATERIAL, METHODEN ZUR HERSTELLUNG UND VERWENDUNGEN[2023/32]
English:A POLOXAMER COMPOSITION FREE OF LONG CIRCULATING MATERIAL AND METHODS FOR PRODUCTION AND USES THEREOF[2017/20]
French:COMPOSITION DE POLOXAMÈRE EXEMPTE D'ELÉMENTS À DURÉE DE CIRCULATION PROLONGÉE, MÉTHODES DE PRODUCTION ET UTILISATIONS[2023/32]
Former [2017/20]POLOXAMERZUSAMMENSETZUNG FREI VON LANGZEITZIRKULIERENDEN MATERIALIEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNGEN DAVON
Former [2017/20]COMPOSITION DE POLOXAMÈRE EXEMPTE DE SUBSTANCE À LONGUE DURÉE DE CIRCULATION, LEURS PROCÉDÉS DE PRODUCTION ET LEURS UTILISATIONS
Entry into regional phase06.02.2017National basic fee paid 
06.02.2017Designation fee(s) paid 
06.02.2017Examination fee paid 
Examination procedure06.02.2017Examination requested  [2017/20]
06.02.2017Date on which the examining division has become responsible
11.09.2017Amendment by applicant (claims and/or description)
28.11.2017Despatch of a communication from the examining division (Time limit: M04)
05.04.2018Reply to a communication from the examining division
28.11.2018Despatch of a communication from the examining division (Time limit: M04)
02.04.2019Reply to a communication from the examining division
12.09.2019Despatch of a communication from the examining division (Time limit: M04)
20.01.2020Reply to a communication from the examining division
22.10.2020Despatch of a communication from the examining division (Time limit: M06)
15.04.2021Reply to a communication from the examining division
29.06.2022Despatch of a communication from the examining division (Time limit: M04)
27.10.2022Reply to a communication from the examining division
06.04.2023Despatch of a communication from the examining division (Time limit: M02)
14.06.2023Reply to a communication from the examining division
20.07.2023Communication of intention to grant the patent
30.11.2023Fee for grant paid
30.11.2023Fee for publishing/printing paid
30.11.2023Receipt of the translation of the claim(s)
Divisional application(s)EP20152586.2  / EP3747448
Opposition(s)11.10.2024No opposition filed within time limit [2024/51]
Fees paidRenewal fee
27.07.2017Renewal fee patent year 03
11.07.2018Renewal fee patent year 04
15.07.2019Renewal fee patent year 05
14.07.2020Renewal fee patent year 06
15.07.2021Renewal fee patent year 07
28.06.2022Renewal fee patent year 08
14.06.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY07.07.2015
HU07.07.2015
CZ10.01.2024
ES10.01.2024
HR10.01.2024
MC10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
IE07.07.2024
CH31.07.2024
[2026/16]
Former [2025/51]CY07.07.2015
CZ10.01.2024
ES10.01.2024
HR10.01.2024
MC10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
IE07.07.2024
CH31.07.2024
Former [2025/36]CZ10.01.2024
ES10.01.2024
HR10.01.2024
MC10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
IE07.07.2024
CH31.07.2024
Former [2025/22]CZ10.01.2024
ES10.01.2024
HR10.01.2024
MC10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
CH31.07.2024
Former [2025/11]CZ10.01.2024
ES10.01.2024
HR10.01.2024
MC10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/49]CZ10.01.2024
ES10.01.2024
HR10.01.2024
PL10.01.2024
RO10.01.2024
SK10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/48]CZ10.01.2024
ES10.01.2024
HR10.01.2024
PL10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/47]ES10.01.2024
HR10.01.2024
PL10.01.2024
SM10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/36]ES10.01.2024
HR10.01.2024
PL10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/35]ES10.01.2024
HR10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/34]HR10.01.2024
NO10.04.2024
RS10.04.2024
GR11.04.2024
IS10.05.2024
Former [2024/33]NO10.04.2024
IS10.05.2024
Former [2024/32]IS10.05.2024
Cited inInternational search[YD] US5567859  (EMANUELE R MARTIN et al.)
 [XP] WO2015058013  (MAST THERAPEUTICS INC et al.)
 [XY]   MARTIN EMANUELE ET AL: "Differential Effects of Commercial-Grade and Purified Poloxamer 188 on Renal Function", DRUGS IN R&D, vol. 14, no. 2, 11 April 2014 (2014-04-11), pages 73 - 83, XP055133853, ISSN: 1174-5886, DOI: 10.1007/s40268-014-0041-0

DOI:   http://dx.doi.org/10.1007/s40268-014-0041-0
 [X]   ANONYMOUS: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 Mast Therapeutics", 26 March 2014 (2014-03-26), pages 1 - 131, XP055209745, Retrieved from the Internet [retrieved on 20150826]
 [A]   JOSEPH G. MOLOUGHNEY ET AL: "Poloxamer 188 (P188) as a Membrane Resealing Reagent in Biomedical Applications", RECENT PATENTS ON BIOTECHNOLOGY, vol. 6, no. 3, 1 November 2012 (2012-11-01), pages 200 - 211, XP055209572, ISSN: 1872-2083, DOI: 10.2174/1872208311206030200

DOI:   http://dx.doi.org/10.2174/1872208311206030200
by applicantUS5696298
 WO9408596
 US4801452
 US4837014
 US4873083
 US4879109
 US4897263
 US4937070
 US4997644
 US5017370
 US5028599
 US5030448
 US5032394
 US5039520
 US5041288
 US5047236
 US5064643
 US5071649
 US5078995
 US5080894
 US5089260
 USRE36665
 US5523492
 US5605687
 US6359014
 US6747064
 US8372387
 US8580245
 US2011044935
 US2011212047
 US2013177524
 WO2006037031
 US2005034790
 WO2009023177
 US2005037157
 WO2006091941
 US2006006862
 US2014045627
 US201462021676
 USRE37285
 USRE38558
 US6761824
 US6977045
 US5567859
 US4522811
 EP0682946
 US2006121016
 US2010316590
 US7846426
 US2009246162
 US8512695
 US2010104542
 US2011033412
 US2010183519
 US8758738
 US2014056839
 US2004258718
 US2009214685
 US2010087501
 US2010249240
 US2011008266
 US2012277199
 US8133918
 US8460644
 US8709385
 US2003206910
 US2006013883
 US2006078616
 US2010310669
 US2012141619
 US8137677
   GRINDEL ET AL., BIOPHARMACEUTICS & DRUG DISPOSITION, vol. 23, 2002, pages 87 - 103
   BIOCHEM, vol. 11, 1972, pages 1726
   REEVE, L.E. ET AL.: "The Poloxamers: Their Chemistry and Medical Applications, in Handbook of Biodegradable Polymers", 1997, HARDWOOD ACADEMIC PUBLISHERS
   SCHMOLKA, J, AM. OIL CHEM. SOC., vol. 54, 1977, pages 110 - 116
   EMANUELE; BALASUBRAMANIAN, DRUGS R D, vol. 14, 2014, pages 73 - 83
   GRINDEL ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 90, 2002, pages 1936 - 1947
   ARMSTRONG ET AL., BIORHEOLOGY, vol. 38, 2001, pages 239 - 247
   CHANG ET AL., BIOPHYSIC. J., vol. 15, 1975, pages 887 - 906
   WEINER ET AL., J PHARM SCI., vol. 74, no. 9, 1985, pages 922 - 925
   EMANUELE; BALASUBRAMANIAN, DRUGS R D, vol. 14, no. 2, 2014, pages 73 - 83
   MOLOUGHNEY ET AL., RECENT PAT BIOTECHNOL., vol. 6, no. 3, 2012, pages 200 - 211
   KARMARKER: "Poloxamers and their applications", PHARMAINFO, 27 October 2008 (2008-10-27)
   LEE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4524 - 4528
   ISAAC ET AL., J ORTHOP RES., 2010, pages 553 - 558
   FRIM ET AL., NEURO REPORT., vol. 15, 2004, pages 171 - 174
   JUSTICZ ET AL., AM HEART J., vol. 122, no. 3, 1991, pages 671 - 680
   O'KEEFE ET AL., AM. J. CARDIOL., vol. 78, 1996, pages 747 - 750
   QUINN ET AL., EUR J NEUROSCI., vol. 27, no. 1, 2008, pages 43 - 52
   HUNTER ET AL., ANN CLIN LAB SCI., vol. 40, no. 2, 2010, pages 115 - 125
   ADAMS ET AL., SURG. FORUM, vol. 10, 1960, pages 585
   DANIELSON ET AL., J THORAX CARDIOVASC SUNG., vol. 59, no. 2, 1970, pages 178 - 184
   HOPPENSTEADT ET AL., FASEB J, vol. 28, no. 1, 2014
   MAYER ET AL., ANN CLIN LAB SCI., vol. 24, no. 4, 1994, pages 302 - 311
   ADAMS-GRAVES ET AL., BLOOD, vol. 90, 1997, pages 2041 - 2046
   BALLAS ET AL., HEMOGLOBIN, vol. 28, no. 2, 2004, pages 85 - 102
   GIBBS; HAGEMANN, ANN. PHARMACOTHER., vol. 38, 2004, pages 320 - 324
   ORRINGER, JAMA, vol. 286, no. 17, 2001, pages 2099 - 2106
   LANE ET AL., BLOOD, vol. 64, 1984, pages 400 - 405
   SCHAER ET AL., CIRCULATION, vol. 90, no. 6, 1994, pages 2964 - 2975
   KERLETA ET AL., ALTEX., vol. 27, no. 3, 2010, pages 191 - 197
   JEONG B. ET AL., ADV DRUG DEL REV, vol. 54, no. 1, 2002, pages 37 - 51
   QI ET AL., INT. J. PHARM., vol. 337, 2007, pages 178 - 187
   CHANG ET AL., J. CONTROLLED REL., vol. 82, 2002, pages 39 - 50
   CHOI ET AL., INT. J. PHARM., vol. 165, 1998, pages 23 - 32
   YONG ET AL., INT. J. PHARM., vol. 321, 2006, pages 56 - 61
   ELHADY ET AL., SAUDI PHARMACEUTICAL JOURNAL., vol. 11, 2003, pages 159 - 171
   YONG ET AL., EUR. J. PHARM. SCI., vol. 23, 2004, pages 347 - 353
   YUN ET AL., INT. J. PHARM., vol. 189, 1999, pages 137 - 145
   PAEK ET AL., BIOLOGICAL & PHARMACEUTICAL BULLETIN., vol. 29, 2006, pages 1060 - 1063
   CAPPEL ET AL., INT. J. PHARM., vol. 69, 1991, pages 155 - 167
   DESAI ET AL., DRUG DELIV., vol. 14, no. 7, 2007, pages 413 - 426
   MUZIKOVD ET AL., ACTA POL PHARM., vol. 70, no. 6, 2013, pages 1087 - 1096
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.